← Back to Portfolio

Vera Therapeutics

Vera is developing Atacicept, a first and best-in-class antibody to treat IgA Nephropathy (IgAN), a rare auto-immune disease. IgAN is the most common cause of kidney disease after hypertension and diabetes. Vera in-licensed Atacicept from EMD Serono, with compelling Ph 2a data. The company listed on Nasdaq in May 2021 with the ticker VERA

LocationSouth San Francisco, CA
CEOMarshall Fordyce
Partner Kurt von Emster